Canadian Nuclear Laboratories : Canadian Nuclear Laboratories and TRIUMF to Host 11th Targeted-Alpha-Therapy Symposium
Canada's national nuclear laboratory and leading particle accelerator centre partner to host global forum on targeted radiopharmaceutical therapy
CHALK RIVER, Ontario and VANCOUVER, British Columbia, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, and TRIUMF, one of the world's leading particle accelerator centres, jointly announced today that they are partnering to co-host the 11th Targeted-Alpha-Therapy Symposium (TAT11) to be held from April 1 - 5, 2019 at the Fairmont Château Laurier in Ottawa.
TAT11 is a global forum for academic and industry leaders to meet and discuss the latest technical, regulatory and clinical developments in targeted radiopharmaceutical therapy. The potential benefits of targeted-alpha-therapy in the battle against cancer and other diseases are significant. While existing radiation treatments target all cells in the vicinity of a tumor, both healthy and cancerous, targeted-alpha-therapy focuses the treatment application to cancerous or unhealthy cells. This limits the overall radiation dose a patient may receive, holds promise of better patient outcomes, and encourages a faster recovery time following treatment.
In addition to a variety of industry and academic speakers and presentations, the TAT11 conference will feature an exhibition for companies to showcase their products and services, and will include a tour of the Chalk River Laboratories.
"Targeted-alpha-therapy is one of the most promising areas of nuclear medicine, and could represent a leap forward in radiation therapy," commented Kathy McCarthy, Lab Director, CNL. "Given CNL's history as a world-leader in the development and delivery of medical isotope technology, hosting this important international conference alongside TRIUMF, a leader in subatomic physics, was a natural fit. We look forward to welcoming participants from around the globe to discuss this exciting medical technology."
As part of Atomic Energy of Canada Limited's (AECL) Federal Nuclear S&T Work Plan, CNL is conducting research to evaluate alpha therapy delivery methods. This includes the construction of a small alpha radioisotope generator to provide isotopes for CNL and its collaborators. CNL is also taking the necessary steps to grow and expand its resources and capabilities to pursue related research projects, including work alongside TRIUMF.
"Canada has an existing and powerful particle accelerator infrastructure capable of enabling a greater supply of targeted-alpha-therapy isotopes," explains Paul Schaffer, TRIUMF Associate Lab Director - Life Sciences Division. "It's very fitting to be hosting the next conference here and I am looking forward to both learning from others and advocating for what Canada can contribute to this exciting field.
"TRIUMF has established the feasibility of producing important targeted-alpha-therapy isotopes such as Ac - 225 using its 500 MeV cyclotron; and is also in the process of upgrading its infrastructure to improve safety and reliability of large-scale, accelerator-based isotope production," explains Schaffer.
"Both CNL and TRIUMF are committed to improving the health of Canadians through nuclear medicine, and TAT11 is an important medium to foster international partnerships and collaborations that are necessary to advance this therapy," added Corey McDaniel, Vice-President, Business Development with CNL. "It is our hope that this forum will build awareness around alpha therapy and spur further research to accelerate the development of these isotopes."
For more information on TAT11, including a detailed conference itinerary and exhibitor information, please visit www.tat11.com.
Canadian Nuclear Laboratories is a world leader in nuclear science and technology offering unique capabilities and solutions across a wide range of industries. Actively involved with industry-driven research and development in nuclear, transportation, clean technology, energy, defense, security and life sciences, we provide solutions to keep these sectors competitive internationally.
With ongoing investments in new facilities and a focused mandate, Canadian Nuclear Laboratories is well positioned for the future. A new performance standard reinforced with a strong safety culture underscores every activity.
Established in 1968 in Vancouver, TRIUMF is Canada's particle accelerator centre. The lab is a hub for discovery and innovation inspired by a half-century of ingenuity in answering nature's most challenging questions. Powered by its complement of top talent and accelerator infrastructure - including the world's largest cyclotron - TRIUMF is driving the leading edges of advanced isotope science, innovation, and technologies to address fundamental and applied problems in particle and nuclear physics, and the materials and life sciences. In collaboration with 20 Canadian universities, TRIUMF's diverse community of nearly 600 multidisciplinary researchers, engineers, technicians, tradespeople, staff, and students create a unique incubator for Canadian excellence, as well as a portal to premier global collaborations. At TRIUMF, we drive more than scientific discovery -- our passion for understanding everything from the nature of the nucleus to the cosmos creates into inspiration, improved health, economic opportunity, and a better world for all.
For more information see http://www.triumf.ca. Connect on Twitter, Facebook, and Instagram: TRIUMFlab
Director, Corporate Communications
Head, Strategic Communications
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Canadian Nuclear Laboratories via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Kofax Intelligent Automation Deployment at Davies Turner Wins Ventana Award for Overall Digital Leadership17.10.2018 12:00 | Pressemelding
Project Recognized for Driving Real-Time Insight into Shipments and Inventory to Transform the Customer Experience; Other Kofax Customers also Receive Accolades IRVINE, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Kofax ® , a leading supplier of intelligent automation (IA) software to digitally transform end-to-end business processes, today announced its customer Davies Turner, one of the UK’s leading multimodal freight forwarding and logistics companies, won the 2018 Overall Digital Leadership Award from Ventana Research for its successful implementation of Kofax Intelligent Automation. Kofax customers Pinnacol Assurance and PITT-OHIO were also recognized. “Davies Turner’s commitment to automation was ambitious but the perfect match for Kofax Intelligent Automation,” said Reynolds C. Bish, Chief Executive Officer of Kofax. “This award is a great illustration of how Kofax enables increased productivity to help organizations remain on track for profitable growth and significant competitive
2018 European Cost Insight Product Cost Management Conference17.10.2018 10:00 | Pressemelding
Companies from Across Europe to Gather and Discuss How PCM Strategies & Technologies Improve Profitability & Accelerate Design to Delivery Time CONCORD, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- aPriori, the leading provider of enterprise product cost management (PCM) software solutions, announces today that it will host the European Cost Insight Product Cost Management Conference on November 26-28, 2018. This year’s event is being held at Hilton Amsterdam Airport Schiphol in Amsterdam, The Netherlands. This event is open to both aPriori customers and representatives from any manufacturers that are interested in learning more about product cost management technology and best practices. Visit the Cost Insight 2018 Event Website for complete information and register for this year’s program. Why Should You Attend Cost Insight 2018? As pressure increases to deliver innovative and customized products to market faster, manufacturers are struggling to maintain product profits and accelerate de
In-Memory Computing Summit North America 2018 Lays Out Vision for Digital Technology Evolution, Provides Practical Advice for Addressing Performance and Scalability Challenges17.10.2018 09:00 | Pressemelding
Keynotes, Breakout Sessions from Industry Leaders and Technology Experts Offer Actionable Advice on Navigating the Trends, Challenges and Solutions of Digital Transformation FOSTER CITY, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, today discussed the success of the fourth annual In-Memory Computing Summit® North America, which took place October 2-3, 2018 at the Hyatt Regency San Francisco Airport. The In-Memory Computing Summits (IMCSs), held annually in Europe and North America, are the only industry-wide events focusing on the full range of in-memory computing technologies and solutions. Nearly 450 people representing 227 organizations from 10 countries across 4 continents and 19 U.S. states registered to listen to speakers from American Airlines, ING Belgium, Intel Corp., Oracle, Salesforce.com, Huawei, SNIA, Wellington Management, GridGain Systems and many more. Recordings and sli
IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union17.10.2018 08:00 | Pressemelding
IMRALDITM is approved in the European Union for the same 14 complex autoimmune conditions as its reference product In 2017 Biogen became the first company in Europe with approved biosimilars referencing the three most prescribed anti-TNF biologic treatments BAAR, Switzerland, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Samsung Bioepis Co. Ltd, a joint venture between Samsung BioLogics and Biogen (Nasdaq: BIIB) today announced the European launch of IMRALDITM, an adalimumab biosimilar referencing Humira®.1 IMRALDI is approved in Europe for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis and uveitis. The launch of IMRALDI completes Biogen’s portfolio of three anti-TNF biosimilars in Europe, with BENEPALITM (etanercept), a biosimilar referencing Enbrel® 2, and FLIXABITM (inflixi
Atico Produces 5.36 Million Pounds of Cu and 3,010 Ounces of Au in Third Quarter 201816.10.2018 22:30 | Pressemelding
VANCOUVER, British Columbia, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) announces its operating results for the three months ended September 30, 2018 from its El Roble mine. Production for the quarter totaled 5.36 million pounds of copper and 3,010 ounces of gold in concentrates, an increase of 5% for copper and 6% for gold, respectively, over the same period in 2017. “We are pleased to report another strong quarter of production as the El Roble mine continues to operate at a steady state level while the Company remains on track to deliver on our 2018 operational objectives,” said Fernando E. Ganoza, CEO. “For remainder of the year, we will continue optimizing the operation and executing the aggressive exploration drilling program at the El Roble property looking for additional mineralization both regionally and at mine vicinity.” Third Quarter Operational Highlights Production of 5.36 million pounds of copper contain
SoftServe’s Research Team Takes Prize at Samsung AI Challenge16.10.2018 21:16 | Pressemelding
Artificial intelligence leveraged to deblur and dehaze photos and videos with exceptional quality AUSTIN, Texas, Oct. 16, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announced its researchers won second place at the Samsung AI Challenge 2018 with innovative neural image restoration enhancement for mobile and embedded devices. “Artificial intelligence is at the center of future-proofing technologies for many businesses today,” said Serge Haziyev, senior vice president for Advanced Technology at SoftServe. “The opportunities for AI are endless and we are proud of our team and their commitment to creating an innovative AI algorithm that pushed the boundaries of existing deblurring and dehazing technologies as part of Samsung’s AI Hackathon.” The winning team, made up of SoftServe research engineers, Volodymyr Budzan and Orest Kupyn, participated in the worldwide event developing a solution that uses state-of-the-art deep learning and computer vi
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom